Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-803 to Treat Leukocyte Adhesion Deficiency Type II
01 déc. 2020 07h00 HE
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor to Collaborate with Frontiers CDG Consortium on Pivotal Trial of CERC-801 for the Treatment of PGM1-CDG
17 nov. 2020 07h00 HE
|
Cerecor Inc.
ROCKVILLE, Md., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for...
Cerecor Reports Third Quarter 2020 Financial Results and Provides Business Update
09 nov. 2020 16h01 HE
|
Cerecor Inc.
On track to complete clinical trial for CERC-002 in cytokine storm-induced COVID-19 ARDS by year end Strengthened leadership team with the appointment of Gilla Kaplan, Ph.D., to the Board of...
Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors
12 oct. 2020 07h00 HE
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor to Present at Upcoming Investor Conferences
10 sept. 2020 07h00 HE
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease
26 août 2020 07h00 HE
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS
13 août 2020 07h00 HE
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor Reports Second Quarter 2020 Financial Results and Business Update
06 août 2020 07h00 HE
|
Cerecor Inc.
-Generated net proceeds of $48 million from equity offering and disposition of Aytu shares to support pipeline advancement -Enrolled first patient in CERC-002 (anti-LIGHT mAb) clinical trial for the...
Cerecor to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
05 août 2020 07h00 HE
|
Cerecor Inc.
ROCKVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric...
Cerecor Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic Malformations
04 août 2020 07h00 HE
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for...